BioAtla Investor Presentation Deck

BioAtla® is a clinical stage company focused on transforming cancer therapy with Conditionally Active Biologics (CABS) Proprietary technology Broad applicability in solid tumors Increases therapeutic bicatla window Two Phase 2 CAB-ADCs, one Phase 2 CAB-CTLA-4 and one Phase 1 dual CAB-bispecific T- cell engager CAB-AXL-ADC (BA3011) advancing potentially registrational trial in sarcoma as well as potentially in other indications Prioritized pipeline Clinical readouts for multiple indications / assets through 2024 Advancing strategic collaboration discussions $141.3 million in cash and cash equivalents as of 09/30/23 Cash position sufficient into 2H 2025 BioAtla| Overview 3

View entire presentation